Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

Oxoeicosanoid Receptor Antibodies

Close filters
No results were found for the filter!
NEW
Validation of the OXE Receptor in transfected HEK293 cells.
OXER (non-phospho), Oxoeicosanoid Receptor...
The non-phospho-OXE receptor antibody is directed against the distal end of the carboxyl-terminal tail of human OXER. It can be used to detect total OXE receptors in Western blots independent of phosphorylation. The OXER antibody can...
$ 375.00 *
Details

The oxoeicosanoid receptor (OXE receptor), encoded by OXER1, is a class A G protein-coupled receptor whose principal endogenous agonist is 5-oxo-eicosatetraenoic acid (5-oxo-ETE). This lipid mediator is generated from the arachidonic acid metabolite 5-HETE by 5-hydroxyeicosanoid dehydrogenase. OXER1 couples predominantly to Gi/o and activates pathways that regulate intracellular calcium mobilization, actin polymerization, and chemotaxis. It is highly expressed in human eosinophils and is also found in neutrophils and macrophages. Activation promotes eosinophil migration and can amplify inflammatory responses, implicating the receptor in allergic diseases such as asthma. The mechanisms governing OXER1 phosphorylation, desensitization, and trafficking remain incompletely characterized. The selective antagonist S-Y048 has reduced allergen-induced eosinophilic inflammation in nonhuman primate models. No OXER1-selective drug has been reported to enter clinical trials or receive approval for therapeutic use. For more information on OXER pharmacology please refer to the IUPHAR database. For further reading refer to:

Bäck M, Dahlén SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, Rovati GE. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev. 2011 Sep;63(3):539-84. doi: 10.1124/pr.110.004184. PMID: 21771892.

Bäck M, Powell WS, Dahlén SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, Rovati GE. Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br J Pharmacol. 2014 Aug;171(15):3551-74. doi: 10.1111/bph.12665. Epub 2014 Jul 12. PMID: 24588652; PMCID: PMC4128057.

The oxoeicosanoid receptor (OXE receptor), encoded by OXER1 , is a class A G protein-coupled receptor whose principal endogenous agonist is 5-oxo-eicosatetraenoic acid (5-oxo-ETE). This lipid... read more »
Close window
Oxoeicosanoid Receptor Antibodies

The oxoeicosanoid receptor (OXE receptor), encoded by OXER1, is a class A G protein-coupled receptor whose principal endogenous agonist is 5-oxo-eicosatetraenoic acid (5-oxo-ETE). This lipid mediator is generated from the arachidonic acid metabolite 5-HETE by 5-hydroxyeicosanoid dehydrogenase. OXER1 couples predominantly to Gi/o and activates pathways that regulate intracellular calcium mobilization, actin polymerization, and chemotaxis. It is highly expressed in human eosinophils and is also found in neutrophils and macrophages. Activation promotes eosinophil migration and can amplify inflammatory responses, implicating the receptor in allergic diseases such as asthma. The mechanisms governing OXER1 phosphorylation, desensitization, and trafficking remain incompletely characterized. The selective antagonist S-Y048 has reduced allergen-induced eosinophilic inflammation in nonhuman primate models. No OXER1-selective drug has been reported to enter clinical trials or receive approval for therapeutic use. For more information on OXER pharmacology please refer to the IUPHAR database. For further reading refer to:

Bäck M, Dahlén SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, Rovati GE. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev. 2011 Sep;63(3):539-84. doi: 10.1124/pr.110.004184. PMID: 21771892.

Bäck M, Powell WS, Dahlén SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, Rovati GE. Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br J Pharmacol. 2014 Aug;171(15):3551-74. doi: 10.1111/bph.12665. Epub 2014 Jul 12. PMID: 24588652; PMCID: PMC4128057.

Recently viewed